That was someone who was taking an extensive dose of Retatrutide, of a GLP-1, to lose weight for a bodybuilding competition, and essentially his pancreas failed. Since 2020, the FDA has worked to restrict peptides that they say carry significant safety risks
Labdoor certified to meet or exceed FDA safety guidelines (per manufacturer) Ingredients: Micronized Creatine Monohydrate: May support strength, power, and ATP regeneration
government to expand access to obesity medicines for millions AI-driven R&D acceleration via partnerships, including NVIDIA 2026 guidance (confidence on display) Revenue: $8083B Non-GAAP EPS: $33.5035.00 Performance margin expected up to 47.5% Dave Ricks Chair & CEO, Eli Lilly and Company: Entering our 150th year with a deep pipeline and platforms like LillyDirect, were positioned to reach more patients than ever. My takeaway Lilly is no longer just executing well its reshaping the pharma operating model: Scale + speed in obesity Platform thinking in GLP-1s and oncology Manufacturing as a strategic moat AI embedded into discovery, not layered on later This isnt a single-franchise story anymore
Notably, AzaA8 displayed a longer half-life yet a higher plasma clearance rate (43.9 ml min 1 kg 1 ) than the Aib8 control (22.6 ml min 1 kg 1 )
Clin Interventions Aging (2019) 14:36773
